Yesterday was dominated by Biogen’s news on their Alzheimer drug, but there was other news including Sarepta getting slapped with a clincial hold, Gilead CEO stepping down and, although not Life Science related, Facebook getting crushed after their earnings. Here is what I’m reading:
- Yesterday afternoon Eisai & Biogen Revealed Promising Alzheimer’s Data But Questions Linger (Xconomy)
- How Often Do Urgent Care Clinics Offer Antibiotics When They Shouldn’t? The answer it seems is too often. I wonder why antibiotics are becoming less and less effective. (Forbes)
- These 10 startups made the cut for XLerateHealth’s sixth cohort (MedCity News). Ten Startups Selected for Inaugural Comcast NBCUniversal LIFT Labs Accelerator, Powered by Techstars (Venture Beat)
- Help wanted: New CEO to run Gilead as John Milligan steps down (EndPoints)
Check out my podcast, Life Sciences Rush Hour – Investing, News, Risk Management and any other topic impacting the space, on Apple Podcasts!
MattCorc 